Tempus Announces Preliminary Fourth Quarter and Full Year 2024 Results
Tempus AI (NASDAQ: TEM) released preliminary, unaudited results for Q4 and full year 2024. The company reported approximate full-year revenue of $693 million, showing ~30% year-over-year growth, and Q4 revenue of $200 million, representing ~35% year-over-year growth.
The company's genomics revenue is expected to grow ~30% in Q4, while data and services revenue is projected to grow ~45%. Tempus expects to achieve ~99% of its 2024 revenue guidance and ~100% of adjusted EBITDA guidance, despite noting some softness in CRO revenues. Both Q4 and full-year results showed continued improvement in adjusted EBITDA compared to previous periods.
These preliminary results are subject to change pending completion of year-end close and review procedures. Final detailed financial results will be reported during the company's first earnings call of 2025.
Tempus AI (NASDAQ: TEM) ha pubblicato i risultati preliminari e non verificati per il quarto trimestre e l'intero anno 2024. L'azienda ha riportato un fatturato annuale di circa 693 milioni di dollari, con una crescita di circa il 30% rispetto all'anno precedente, e un fatturato del Q4 di 200 milioni di dollari, che rappresenta una crescita di circa il 35% anno su anno.
Si prevede che il fatturato genomico dell'azienda cresca di circa il 30% nel Q4, mentre il fatturato derivante da dati e servizi è previsto crescere di circa il 45%. Tempus si aspetta di raggiungere circa il 99% della sua guida sui ricavi per il 2024 e circa il 100% della guida sull'EBITDA rettificato, nonostante abbia notato una certa debolezza nei ricavi CRO. Sia i risultati del Q4 che quelli annuali hanno mostrato un miglioramento continuo nell'EBITDA rettificato rispetto ai periodi precedenti.
Questi risultati preliminari sono soggetti a modifiche in attesa del completamento delle procedure di chiusura di fine anno e revisione. I risultati finanziari finali dettagliati saranno riportati durante la prima chiamata sugli utili dell'azienda nel 2025.
Tempus AI (NASDAQ: TEM) publicó resultados preliminares y no auditados para el cuarto trimestre y el año completo de 2024. La empresa reportó aproximadamente ingresos anuales de 693 millones de dólares, mostrando un crecimiento de aproximadamente el 30% año tras año, y ingresos del cuarto trimestre de 200 millones de dólares, representando un crecimiento de aproximadamente el 35% año con año.
Se espera que los ingresos por genómica de la empresa crezcan aproximadamente un 30% en el cuarto trimestre, mientras que se proyecta que los ingresos por datos y servicios crezcan aproximadamente un 45%. Tempus espera alcanzar aproximadamente el 99% de su guía de ingresos para 2024 y alrededor del 100% de la guía de EBITDA ajustado, a pesar de señalar cierta debilidad en los ingresos CRO. Tanto los resultados del cuarto trimestre como los del año completo mostraron una mejora continua en el EBITDA ajustado en comparación con períodos anteriores.
Estos resultados preliminares están sujetos a cambios pendientes de la finalización del cierre de fin de año y de los procedimientos de revisión. Los resultados financieros finales detallados se informarán durante la primera llamada de ganancias de la empresa en 2025.
템퍼스 AI (NASDAQ: TEM)는 2024년 4분기 및 연간 예비 미감사 결과를 발표했습니다. 회사는 대략 693백만 달러의 연간 수익을 보고하며, 이는 전년 대비 약 30% 성장한 수치이며, 4분기 수익은 2억 달러로, 이는 전년 대비 약 35% 성장한 것을 나타냅니다.
회사의 유전체학 수익은 4분기 동안 약 30% 성장할 것으로 예상되며, 데이터 및 서비스 수익은 약 45% 성장할 것으로 예상됩니다. 템퍼스는 2024년 수익 가이던스의 약 99%와 조정 EBITDA 가이던스의 약 100%를 달성할 것으로 기대하고 있으며, CRO 수익에 대한 다소의 약세를 언급했습니다. 4분기 및 연간 결과 모두 이전 기간에 비해 조정 EBITDA에서 지속적인 개선을 보였습니다.
이 예비 결과는 연말 마감 및 검토 절차 완료를 기다리는 동안 변경될 수 있습니다. 최종 세부 재무 결과는 2025년 회사의 첫 번째 실적 발표에서 보고될 예정입니다.
Tempus AI (NASDAQ: TEM) a publié des résultats préliminaires, non audités pour le quatrième trimestre et l'année entière 2024. L'entreprise a annoncé environ un chiffre d'affaires annuel de 693 millions de dollars, affichant une croissance d'environ 30% par rapport à l'année précédente, et un chiffre d'affaires au Q4 de 200 millions de dollars, représentant une croissance d'environ 35% par rapport à l'année précédente.
Les revenus de l'entreprise liés à la génomique devraient croître d'environ 30% au Q4, tandis que les revenus des données et des services devraient augmenter d'environ 45%. Tempus prévoit d'atteindre environ 99% de ses prévisions de revenus pour 2024 et environ 100% de ses prévisions d'EBITDA ajusté, bien qu'il ait noté une certaine faiblesse dans les revenus CRO. Les résultats du Q4 ainsi que ceux de l'année entière ont montré une amélioration continue de l'EBITDA ajusté par rapport aux périodes précédentes.
Ces résultats préliminaires sont susceptibles d'être modifiés en fonction de l'achèvement de la clôture de fin d'année et des procédures de révision. Les résultats financiers détaillés finaux seront publiés lors de la première conférence sur les résultats de l'entreprise en 2025.
Tempus AI (NASDAQ: TEM) hat vorläufige, ungeprüfte Ergebnisse für das vierte Quartal und das Gesamtjahr 2024 veröffentlicht. Das Unternehmen berichtete von einem Jahresumsatz von etwa 693 Millionen Dollar, was einem Wachstum von etwa 30% im Jahresvergleich entspricht, und einem Umsatz im Q4 von 200 Millionen Dollar, was ein Wachstum von etwa 35% im Jahresvergleich darstellt.
Es wird erwartet, dass die Umsätze im Bereich Genomik im Q4 um etwa 30% wachsen, während die Umsätze aus Daten und Dienstleistungen voraussichtlich um etwa 45% steigen werden. Tempus erwartet, etwa 99% der Umsatzprognose für 2024 und etwa 100% der angepassten EBITDA-Prognose zu erreichen, merkt jedoch eine gewisse Schwäche bei den CRO-Umsätzen an. Sowohl die Ergebnisse des Q4 als auch die Ergebnisse für das Gesamtjahr zeigten eine kontinuierliche Verbesserung des angepassten EBITDA im Vergleich zu vorherigen Zeiträumen.
Diese vorläufigen Ergebnisse sind Änderungen vorbehalten, die nach Abschluss der Jahresabschluss- und Prüfverfahren erfolgen können. Die endgültigen detaillierten finanziellen Ergebnisse werden während des ersten Gewinnaufrufs des Unternehmens im Jahr 2025 bekannt gegeben.
- Full-year revenue growth of ~30% reaching $693 million
- Q4 revenue growth of ~35% reaching $200 million
- Data and services revenue growth of ~45% in Q4
- Genomics revenue growth of ~30% in Q4
- Meeting ~99% of revenue guidance and ~100% of adjusted EBITDA guidance
- Sequential improvement in adjusted EBITDA
- Softness reported in CRO revenues
Insights
The preliminary results showcase impressive growth metrics, with full-year revenue reaching
Meeting
The pending Ambry acquisition signals strategic expansion plans, though investors should note these are preliminary results subject to final audit. The sustained growth in core segments and EBITDA improvements paint a picture of a company successfully monetizing its AI-driven precision medicine platform.
The differentiated growth rates between business segments reveal Tempus's evolving market position. The robust
The softer CRO (Contract Research Organization) performance might reflect broader industry challenges in clinical trial recruitment and execution, but the strength in core businesses demonstrates successful pivot toward data-driven healthcare solutions. The company's ability to maintain growth while improving EBITDA metrics suggests successful scaling of their AI infrastructure and increasing operating leverage.
The upcoming Ambry acquisition could significantly expand Tempus's testing capabilities and data assets, potentially accelerating their AI platform's development through increased data access and clinical insights. This combination of organic growth and strategic expansion positions Tempus well in the rapidly evolving precision medicine landscape.
Full Year 2024 Select, Preliminary, Unaudited Financial Results
-
Revenue of approximately
$693 million 30% growth year-over-year - Continued improvement in adjusted EBITDA compared to the prior year
Fourth Quarter 2024 Select, Preliminary, Unaudited Financial Results
-
Revenue of approximately
$200 million 35% year-over-year - Continued trend of sequential improvement in adjusted EBITDA in the fourth quarter of 2024
“We concluded 2024 with continued strength in our core businesses, as genomics revenue is expected to grow at ~
This announcement comes ahead of the Company’s presentation today at the 43rd Annual J.P. Morgan Healthcare Conference. A live webcast to the presentation and our updated investor deck, which includes an update on the expected closing of our Ambry acquisition, can be found on our investor relations website at investors.tempus.com.
Tempus has not completed preparation of its financial statements for the fourth quarter or full year 2024. The estimates disclosed in this release for the fourth quarter and year ended December 31, 2024, are preliminary, and unaudited and inherently uncertain, and therefore subject to change as Tempus completes preparation of its financial results for these periods. Tempus is in the process of completing its customary year-end close and review procedures for the quarter and year ended December 31, 2024, and there can be no assurance that final results for these periods will not differ from these estimates, and any such difference may be material. During the preparation of Tempus’ consolidated financial statements for the year ended December 31, 2024, Tempus or its independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary financial estimates presented herein.
Tempus plans to report its complete fourth quarter and full year 2024 financial results during its first earnings call of 2025.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Non-GAAP Financial Measures
In addition to the financial information presented in this release in accordance with accounting principles generally accepted in
Tempus believes this non-GAAP financial measure is useful to investors and others because it allows for additional information with respect to financial measures used by management in its financial and operational decision-making and it may be used by institutional investors and the analyst community to help them analyze the health of Tempus’ business. In particular, Adjusted EBITDA is a key measurement used by Tempus management to make operating decisions, including those related to analyzing operating expenses, evaluating performance, and performing strategic planning and annual budgeting. However, there are a number of limitations related to the use of non-GAAP financial measures, and Adjusted EBITDA should be considered in addition to, not as a substitute for or in isolation from, net loss, the most comparable GAAP measure. Other companies, including companies in our industry, may calculate this non-GAAP financial measure differently or not at all, which reduces its usefulness as a comparative measure.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, Tempus’ preliminary, unaudited financial results for fourth quarter and full year 2024; Tempus’ expected financial results for full year 2025; the contributions of Tempus’ research and findings to the larger scientific community, the use of Tempus’ products and services to advance clinical care for patients, and the pending acquisition of Ambry. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments, including our ability to consummate the acquisition of Ambry Genetics and the related financing on the terms described herein or at all and, if consummated, to realize the expected benefits of such acquisition; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Form 10-Q for the quarter ended September 30, 2024 filed with the Securities and Exchange Commission (“SEC”) on November 4, 2024, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113895130/en/
Erin Carron
media@tempus.com
Source: Tempus AI, Inc.
FAQ
What was Tempus AI's (TEM) revenue growth in Q4 2024?
How much revenue did Tempus (TEM) generate in full-year 2024?
What was the growth rate of Tempus's (TEM) data and services revenue in Q4 2024?
Did Tempus (TEM) meet its 2024 financial guidance?
What challenges did Tempus (TEM) face in Q4 2024?
